Skip to main content
SpringerLink
Log in

Economics of dialysis

  • Chapter
Replacement of Renal Function by Dialysis

Abstract

In the early 1960s when the first chronic dialysis programs were being set up in the United States and elsewhere, it is doubtful that even the most enthusiastic proponents of the new therapy had any notion of the remarkable extent to which it would grow over the ensuing years. Now, less than four decades later, over one million patients worldwide with end-stage renal disease (ESRD) are being kept alive by chronic dialysis. The incidence and prevalence of treated ESRD has for many years been growing inexorably at rates of 4–8% per annum in the developed world (1). Furthermore, this growth has now extended from the wealthy countries of the developed world to the less wealthy countries of Eastern Europe, Asia and Latin America, where growth rates exceed 10% per annum. The result of this is that ESRD is now a major international public health issue.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Lysaght MJ. Maintenance dialysis population dynamics: Current trends and long-term implications. J Am Soc Nephrol. 2002:13(Suppl. 1):S37–40.

    Google Scholar 

  2. Klefter R, Nielsen B. A hundred billion dollars a year on dialysis. How to calculate and what to compare. Int J Artif Organs. 1998;21:319–20.

    PubMed  CAS  Google Scholar 

  3. US Renal Data System, USRDS. 2003 Annual Data Report; Chapter 11; Economic Costs of ESRD. Atlas of End Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2003.

    Google Scholar 

  4. Manns BJ, Taub KJ, Donaldson C. Economic evaluation and end-stage renal disease: from basics to bedside. Am J Kidney Dis. 2000;36:12–28.

    Article  PubMed  CAS  Google Scholar 

  5. Dyck RF, Tan L. Rates and outcomes of diabetic endstage renal disease among registered native people in Saskatchewan. CMAJ. 1994;150:203–8.

    PubMed  CAS  Google Scholar 

  6. Hoy W. Renal disease in Australia aborigines. Nephrol Dial Transplant. 2000;15:1293–7.

    Article  PubMed  CAS  Google Scholar 

  7. Lightstone L, Rees AJ, Tomson C, Walls J, Winearlis CG, Feehally J. High incidence of end-stage renal disease in IndoAsians in the UK. Q J Med. 1995;88:191–5.

    CAS  Google Scholar 

  8. Trehan A, Winterbottom J, Lane B et al. End-stage renal disease in descendants of the Indian subcontinent living in the north west of England. Q J Med. 2003;96:499504.

    Google Scholar 

  9. Lai KN, Li SCS, Chan TM. End-stage renal disease among Asians. Int J Artif Organs. 1998;21:67–71.

    PubMed  CAS  Google Scholar 

  10. US Renal Data System, USRDS. 2003 Annual Data Report; Chapter 2; Incidence and Prevalence of ESRD. Atlas of End Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2003.

    Google Scholar 

  11. CORR Report.

    Google Scholar 

  12. http://www.quasi-niere.de

  13. http://www.renareg.com

  14. Levinsky NG, Rettig RA. Special Report: The Medicare End-Stage Renal Disease Program. N Engl J Med. 1991; 324:1143–8.

    Article  PubMed  CAS  Google Scholar 

  15. US Renal Data System, USRDS. 2002 Annual Data Report. Chapter 11. Provider Characteristics; Atlas of End Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2002.

    Google Scholar 

  16. http://www.nkfs.org

  17. Blake PG, Mendelssohn DC, Toffelmire EB. New developments in hemodialysis delivery in Ontario, 1995–2000. Nephrol New Issues. 2000;14:72–80.

    CAS  Google Scholar 

  18. Blake PG. Dialysis in Australia: changes in the delivery model. Nephrol New Issues. 2001:15:51–5.

    CAS  Google Scholar 

  19. Mendelssohn DC, Blake PG. Shifting sand: dialysis funding and modality distribution in Ontario. Nephrol News Issues. 1999;13:31–7.

    PubMed  CAS  Google Scholar 

  20. Gaffney D, Pollock AM, Price D, Shoul J. The private finance initiative: the politics of the private finance initiative and the new NHS. VMJ. 1999,319:249–53.

    CAS  Google Scholar 

  21. Jacobs C. The costs of dialysis treatments for patients with end-stage renal disease in France. Nephrol Dial Transplant. 1997:12(Suppl. 1):29–32.

    Article  PubMed  Google Scholar 

  22. Piccoli G, Formica M, Mangeiaortti G et al. The costs of dialysis in Italy. Nephrol Dial Transplant. 1997;12(Suppl. 1): 33–44.

    Article  PubMed  Google Scholar 

  23. De Vecchi AF, Dratwa M, Wiedemann ME. Healthcare systems and end-stage renal disease (ESRD) therapies — an international review: costs and reimbursement/funding of ESRD therapies. Nephrol Dial Transplant. 1999;14 (Suppl. 6):31–41.

    Article  PubMed  Google Scholar 

  24. Igelehart JK. Germany’s health care system. N Engl J Med. 1991;324:503–8.

    Article  Google Scholar 

  25. Levinsky NG. The organization of medical care: lessons from the Medicare End Stage Renal Disease Program. N Engl J Med. 1993;329:1395–9.

    Article  PubMed  CAS  Google Scholar 

  26. Iglehart JK. Health Policy Report. The American Health Care System. The End Stage Renal Disease Program. N Engl J Med. 1993;328:366–71.

    Google Scholar 

  27. Devereaux PJ, Schunemann HJ, Ravindran N et al. Comparison of mortality between private for-profit and private not-for-profit hemodialysis centers: a systematic review and meta-analysis. J Am Med Assoc. 2002;288:2449–57.

    Article  CAS  Google Scholar 

  28. Garg PP, Frick KD, Diener-West M, Powe NR. Effect of the ownership of dialysis facilities on patients’ survival and referral for transplantation. N Engl J Med. 1999;341: 1653–60.

    Article  PubMed  CAS  Google Scholar 

  29. Frankenfield DL, Sugarman JR, Presley RJ, Helgerson SD, Rocco MV. Impact of facility size and profit status on intermediate outcomes in chronic dialysis patients. Am J Kidney Dis. 2000;36:318–26.

    Article  PubMed  CAS  Google Scholar 

  30. Port FK, Wolfe RA, Held PJ. Ownership of dialysis facilities and patients’ survival (letter). N Engl J Med. 2000;342: 1053–4.

    Article  PubMed  CAS  Google Scholar 

  31. http://www.baxter.com

  32. http://www.fmc-ag.com

  33. http://www.gambro.com

  34. Peeters P, Rublee D, Just PM, Joseph A. Analysis and interpretation of cost data in dialysis: review of Western European literature. Health Policy. 2000;54:209–27.

    Article  PubMed  CAS  Google Scholar 

  35. Getzen TE. Economic evaluation of health services. In: editor. Health Economics. New York: John Wiley, 1997:000–00.

    Google Scholar 

  36. Sheingold S, Churchill DN, Muirhead N et al. The impact of recombinant erythropoietin on medical care costs for hemodialysis in Canada. Soc Sci Med. 1992;34:983–91.

    Article  PubMed  CAS  Google Scholar 

  37. Stevens ME, Summerfield GP, Hall AA et al. Cost benefits of low dose subcutaneous erythropoietin in patients with anemia of end-stage renal disease. Br Med J. 1992;304:474–7.

    Article  CAS  Google Scholar 

  38. Chertow GM. Issues in evaluating the cost-effectiveness of dialysis. Semin Dial. 1999;12:355–8.

    Article  Google Scholar 

  39. McFarlane PA, Bayoumi AM, Pierratos A, Redelmeier DA. The quality of life and cost utility of home nocturnal and conventional in-center hemodialysis. Kidney Int. 2003;64: 1004–11.

    Article  PubMed  Google Scholar 

  40. Williams A. Economics of coronary artery bypass grafting. Br Med J. 1985;291:326–9.

    Article  CAS  Google Scholar 

  41. Mason JM. Cost-per-QALY league tables: their role in pharmacoeconomic analysis. Pharmaeconomics. 1994;5: 472–81.

    Article  CAS  Google Scholar 

  42. Winkelmayer WC, Weinstein MC, Mittlemann MA, Glynn RJ, Pliskin JS. Heath economic evaluations: the special case of end stage renal disease treatment. Med Decis Making. 2002; 22:417–30.

    PubMed  Google Scholar 

  43. Petrou S, Malek M, Davey PG. Reliability of cost-utility estimates in cost-per-QALY league tables. Pharmaeconomics. 1993;3:425–6.

    Article  Google Scholar 

  44. De Wit GA, Busschbach JJ, De Charro FT. Sensitivity and perspective in the valuation of health status: whose values count? Health Econ. 2000;9:109–26.

    Article  PubMed  Google Scholar 

  45. Mitton C, Donaldson C. Tools of the trade: a comparative analysis of approaches to priority setting in healthcare. Health Sev Manage Res.2003;16:96–105.

    Article  CAS  Google Scholar 

  46. Gelber RD, Goldhirsch A, Cole BF. Evaluation of effectiveness: Q-TwiST. Cancer Treat Rev. 1993;19:73–84.

    Article  PubMed  Google Scholar 

  47. Hamel MB, Phillips RS, Davis RB et al. Outcomes and costeffectiveness of initiating dialysis and continuing aggressive care in seriously ill hospitalized adults. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Ann Intern Med. 1997; 127:195–202.

    Article  PubMed  CAS  Google Scholar 

  48. Manns B, Doig CJ, Lee H et al. Cost of acute renal failure requiring dialysis in the intensive care unit: clinical and resource implications of renal recovery. Crit Care Med. 2003; 31:449–55.

    Article  PubMed  Google Scholar 

  49. US Renal Data System, USRDS. 1999 Annual Data Report. Chapter 10. The Economic Cost of ESRD; Atlas of End Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1999.

    Google Scholar 

  50. Van Biesen W, Vanholder R, Veys N, Dhondt A, Lameire N. An evaluation of an integrative care approach for end-stage renal disease patients. J Am Soc Nephrol. 2000;11:116–25.

    PubMed  Google Scholar 

  51. Sennfalt K, Magnusson M, Carlsson P. Comparison of hemodialysis and peritoneal dialysis — a cost-utility analysis. Pert Dial Int. 2002;22:39–47.

    Google Scholar 

  52. De Wit GA, Ramsteijn PG, de Charro FT. Economic evaluation of end stage renal disease treatment. Health Policy. 1998;44:215–32.

    Article  PubMed  Google Scholar 

  53. Miskulin DC, Meyer KB, Athienites NV et al. Comorbidity and other factors associated with modality selection and incident dialysis patients: The CHOICE Study. Choices for Healthy Outcomes in Caring for End-stage renal disease. Am J Kidney Dis. 2002;39:324–36.

    Article  PubMed  Google Scholar 

  54. Goeree R, Manalich J, Grootendorst P, Beecroft ML, Churchill DN. Cost analysis of dialysis treatments for endstage renal disease (ESRD). Clin Invest Med. 1995;18:455–64.

    PubMed  CAS  Google Scholar 

  55. Lee H, Manns B, Taub K et al. Cost analysis of patients with end-stage renal disease: the impact of dialysis modality and dialysis access. Am J Kidney Dis. 2002;40:611–22.

    Article  PubMed  Google Scholar 

  56. Pierratos A, Ouwendyke M, Francoeur R et al. Nocturnal hemodialysis: three-year experience. J Am Soc Nephrol. 1998; 9:859–68.

    PubMed  CAS  Google Scholar 

  57. Lindsay RM, Leitch R, Heidenheim AP, Kortas C. The London daily/nocturnal hemodialysis study — study design, morbidity and mortality results. Am J Kidney Dis. 2003, 42(Suppl. 1):5–12.

    Article  PubMed  Google Scholar 

  58. Kroeker A, Clark WF, Heidenheim AP et al. An operating cost comparison between conventional and home quotidian hemodialysis. Am J Kidney Dis. 2003;42(Suppl. 1):49–55.

    Article  PubMed  Google Scholar 

  59. McFarlane PA, Pierratos A, Redelmeier DA. Cost savings of home nocturnal vs. conventional in-center hemodialysis. Kidney Int. 2002;62:2216–22.

    Article  PubMed  Google Scholar 

  60. Blake PG, Floyd J, Spanner E, Peters K. How much extra does ‘adequate’ peritoneal dialysis cost? Pert Dial Int. 1996; 16(Suppl.):S171–5.

    Google Scholar 

  61. Gokal R. Newer peritoneal dialysis solutions. Adv Ren Replace Ther. 2000;7:302–9.

    Article  PubMed  CAS  Google Scholar 

  62. Weijnen TJ, van Hamersvelt HW, Just PM et al. Economic impact of extended time on peritoneal dialysis as a result of using polyglucose: the application of a Markov chain model to forecast changes in the development of the ESRD programme over time. Nephrol Dial Transplant. 2003;18:390–6.

    Article  PubMed  CAS  Google Scholar 

  63. Kufman JS, Reda DJ, Fye CL et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med. 1998;27:339,578–83.

    Article  Google Scholar 

  64. Page DE, House A. Important cost differences of blood transfusion and erythropoietin between hemodialysis and peritoneal dialysis patients. Adv Pert Dial. 1998;14:87–9.

    CAS  Google Scholar 

  65. Murphy SW, Foley RN, Barrett BJ et al. Comparative hospitalization of hemodialysis and peritoneal dialysis patients in Canada. Kidney Int. 2000;57:2557–63.

    Article  PubMed  CAS  Google Scholar 

  66. Habach G, Bloembergen WE, Maujer EA, Wolfe RA, Port FK. Hospitalization among United States dialysis patients: hemodialysis versus peritoneal dialysis. J Am Soc Nephrol. 1995;5:1940–8.

    PubMed  CAS  Google Scholar 

  67. Bruns FJ, Seddon P, Saul M, Ziedel ML. The cost of caring for end-stage kidney disease patients: an analysis based on hospital financial transaction records. J Am Soc Nephrol. 1998;9:884–90.

    PubMed  CAS  Google Scholar 

  68. McMurray SD, Miller J. Impact of capitation on freestanding dialysis facilities: can you survive? Am J Kidney Dis. 1997;30:542–8.

    Article  PubMed  CAS  Google Scholar 

  69. Moore R, Marriott N. Cost and price in the NHS: the importance of monetary value in the decision-making framework — the case of purchasing renal replacement therapy. Health Serv Manag Res. 1999;12:1–14.

    CAS  Google Scholar 

  70. Kher V. End-stage renal disease in developing countries. Kidney Int. 2002;62:350–62.

    Article  PubMed  Google Scholar 

  71. Blake PG. Peritoneal dialysis in Asia: an external perspective. Pert Dial Int. 2002;22:258–64.

    Google Scholar 

  72. Li PK, Chow KM. The cost barrier to peritoneal dialysis in the developing world — an Asian perspective. Pert Dial Int. 2001,(Suppl. 3):S307–13.

    Google Scholar 

  73. Abraham G, Mathew M, Hinduja A, Padma G. Continuous ambulatory peritoneal dialysis. J Indian Med Assoc. 2002; 100:184–7.

    PubMed  Google Scholar 

  74. Correa-Rotter R. The cost barrier to renal replacement therapy and peritoneal dialysis in the developing world. Pert Dial Int. 2001;21(Suppl. 3):5314–17.

    Google Scholar 

  75. Young EW, Mauger EA, Jiang KH, Porte FK, Wolfe RA. Socioeconomic status and end-stage renal disease in the United States. Kidney Int. 1994;45:907–11.

    Article  PubMed  CAS  Google Scholar 

  76. Perneger TV, Whelton PK, Klag MJ. Race and end-stage renal disease: socioeconomic status and access to health care as mediating factors. Arch Intern Med. 1995;155:1201–8.

    Article  PubMed  CAS  Google Scholar 

  77. Roderick P, Clements S, Stone N, Martin D, Diamond I. What determines geographical variation in rates of acceptance onto renal replacement therapy in England? J Health Serv Res Pol. 1999;4:139–146.

    CAS  Google Scholar 

  78. Roderick PJ, Ferris G, Feest TG. The provision of renal replacement therapy for adults in England and Wales: recent trends and future directions. Q J Med. 1998;91:581–7.

    Article  CAS  Google Scholar 

  79. Stanton J. The cost of living: kidney dialysis, rationing and health economics in Britain, 1965–1996. Soc Sci Med. 1999; 49:1169–82.

    Article  PubMed  CAS  Google Scholar 

  80. Lameire N, Joffe P, Wiedemann ME. Healthcare systems and end-stage renal disease (ESRD) therapies — an international review: an overview. Nephrol Dial Transplant. 1999; 14(Suppl. 6):3–9.

    Article  PubMed  Google Scholar 

  81. Horl WH, de Alvaro F, Williams PF. Healthcare systems and end-stage renal disease (ESRD) therapies — an international review: access to ESRD treatments. Nephrol Dial Transplant. 1999;14(Suppl. 6):10–15.

    Article  PubMed  Google Scholar 

  82. Blake PG. Factors affecting international utilization of peritoneal dialysis: implications for increasing utilization in the United States. Semin Dial. 1999;12:365–9.

    Article  Google Scholar 

  83. Blake PG, Finkelstein FO. Why is the proportion of patients doing peritoneal dialysis declining in North America? Pert Dial Int. 2001;21:107–14.

    CAS  Google Scholar 

  84. Nissenson AR, Prichard SS, Cheng IK et al. Non-medical factors that impact on ESRD modality selection. Kidney Int. 1993;40:5120–7.

    Google Scholar 

  85. Jung B, Blake PG, Mehta RL, Mendelssohn DC. AttitudeS of Canadian nephrologists toward dialysis modality selection. Pert Dial Int. 1999;19:263–8.

    CAS  Google Scholar 

  86. Mendelssohn DC, Mullaney SR, Jung B, Blake PG, Mehta RL. What do American nephrologists think about dialysis modality selection? Am J Kidney Dis. 2001;37: 22–9.

    PubMed  CAS  Google Scholar 

  87. Wang TE, Abraham G, Akiba T et al. Peritoneal dialysis in Asia in the 21st century: perspectives on obstacles to peritoneal dialysis therapy in Asian countries. Pert Dial Int. 2002;22:243–8.

    CAS  Google Scholar 

  88. Lai KN, Lo WK. Optimal peritoneal dialysis for patients from Hong Kong. Pert Dial Int. 1999;19(Suppl. 3):S26–31.

    Google Scholar 

  89. NKF-K/DOQI. Clinical practice guidelines for anemia in chronic kidney disease: update 2000. Am J Kidney Dis. 2001; 37:5182–228.

    Google Scholar 

  90. Tonelli M, Winkelmayer WC, Jindal KK, Owen WF, Manns BJ. The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int. 2003;64:295–304.

    Article  PubMed  CAS  Google Scholar 

  91. Collins AJ, Ma JZ, Xia A, Ebben J. Trends in anemia treatment with erythropoietin usage and patient outcomes. Am J Kidney Dis. 1998;32(Suppl. 4):S133–41.

    Article  PubMed  CAS  Google Scholar 

  92. Besarab A, Flaharty KK, Erslev AJ et al. Clincal pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration. J Am Soc Nephrol. 1992;2:1405–16.

    PubMed  CAS  Google Scholar 

  93. Hynes DM, Stroupe KT, Greer JW et al. Potential cost savings of erythropoietin administration in end-stage renal disease. Am J Med. 2002;112:169–75.

    Article  PubMed  Google Scholar 

  94. McDougall IC, Chandler G, Elston O, Harchowal J. Beneficial effects of adopting an aggressive intravenous iron policy in a hemodialysis unit. Am J Kidney Dis. 1999;34 (Suppl. 2):S40–6.

    Article  Google Scholar 

  95. Quarles LD, Yohay DA, Carroll BA et al. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int. 1994;45:1710–21.

    Article  PubMed  CAS  Google Scholar 

  96. Sullivan JD. The economics of dialyzer reuse in ESRD. Nephrol News Issues. 2002;16:32–34,36,38.

    Google Scholar 

  97. Manns BJ, Taub K, Richardson RM, Donaldson C. To reuse or not to reuse? An economic evaluation of hemodialyzer reuse versus conventional single-use hemodialysis for chronic hemodialysis patients. Int J Technol Assess Health Care. 2002;18:81–93.

    PubMed  Google Scholar 

  98. Ozgen H, Ozcan YA. A national study of efficiency for dialysis centers; an examination of market competition and facility characteristics for production of multiple dialysis outputs. Health Sev Res. 2002;37:711–32.

    Article  Google Scholar 

  99. Levin A, Lewis M, Mortiboy P et al. Multidisciplinary predialysis programs: quantification and limitations of their impact on patient outcomes in two Canadian settings. Am J Kidney Dis. 1997;29:533–40.

    Article  PubMed  CAS  Google Scholar 

  100. Obrador GT, Arora P, Kausz AT, Pereira BJ. Pre-end-stage renal disease care in the United States: a state of disrepair. J Am Soc Nephrol. 1998;9(Suppl. 12):S44–54.

    PubMed  CAS  Google Scholar 

  101. Obrador GT, Ruthazer R, Arora P, Kausz AT, Pereira BJ. Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. J Am Soc Nephrol. 1999;10:1793–800.

    PubMed  CAS  Google Scholar 

  102. Collins AJ. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations. Nephrol Dial Transplant. 2003;18(Suppl. 2):2–6.

    Google Scholar 

  103. Winkelmayer WC, Owen WF, Levin R, Avorn J. A propensity analysis of late versus early nephrologist referral and mortality on dialysis. J Am Soc Nephrol. 2003;14: 486–92.

    Article  PubMed  Google Scholar 

  104. McLaughlin K, Manns B, Culleton B, Donaldson C, Taub K. An economic evaluation of early versus late referral with progressive renal insufficiency. Am J Kidney Dis. 2001,38: 1122–8.

    Article  PubMed  CAS  Google Scholar 

  105. Trivedi HS, Pang MMH, Campbell A, Saab P. Slowing the progression of chronic renal failure: economic benefits and patients’ perspectives. Am J Kidney Dis. 2002;39:721–9.

    Article  PubMed  Google Scholar 

  106. Harris LE, Luft FC, Rudy DW, Kesterson JG, Tierney WM. Effects of multidisciplinary case management in patients with chronic renal insufficiency. Am J Med. 1998:105: 464–71.

    Article  PubMed  CAS  Google Scholar 

  107. Ragson SA, Chemleski BL, Ho S et al. Benefits of a multidisciplinary predialysis program in maintaining employment among patients on home dialysis. Adv Pert Dial. 1996;12: 132–5.

    Google Scholar 

  108. Clark WF, Churchill DN, Forwell L, Macdonald G, Foster S. To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor treatment for diabetic nephropathy. CMAJ. 2000;162:195–8.

    PubMed  CAS  Google Scholar 

  109. McAlister FA, Lawson FM, Teo KK, Armstrong PW. A systematic review of randomized trials of disease management programs in heart failure. Am J Med. 2001;110: 378–84.

    Article  PubMed  CAS  Google Scholar 

  110. Norris SL, Nichols PJ, Caspersen CJ et al. The effectiveness of disease and case management for people with diabetes. A systematic review. Am J Prey Med. 2002;22(Suppl. 4): 15–38.

    Article  Google Scholar 

  111. Daly C, Campbell M, Cody J. Double bag or Y-set versus standard transfer systems for continuous ambulatory peritoneal dialysis in end-stage renal disease. Cochrane Database Syst Rev. 2001;(2): CD003078.

    Google Scholar 

  112. Pauker SG, Kassirer JP. Decision analysis. N Engl J Med. 1987;316:250–8.

    Article  PubMed  CAS  Google Scholar 

  113. Knoll GA, Nicholl G. Dialysis, kidney transplantation, or pancreatic transplantation for diabetes mellitus and renal failure: A decision analysis of treatment options. J Am Soc Nephrol. 2003;14:500–15.

    Article  PubMed  Google Scholar 

  114. Miskulin DC, Meyer KB, Martin AA et al. Comorbidity and its change predict survival in incident dialysis patients. Am J Kidney Dis. 2003;41:149–61.

    Article  PubMed  Google Scholar 

  115. Nissenson AR, Rettig RA. Medicare’s End-Stage Renal Disease Program: Current status and future prospects. Nephrologia. 1999;19:210–22.

    Google Scholar 

  116. Garella S. The costs of dialysis in the USA. Nephrol Dial Transplant. 1997;12(Suppl. 1):10–21.

    PubMed  Google Scholar 

  117. Xue JL, Ma JZ, Louis TA, Collins AJ. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol. 2001;12:2753–8.

    PubMed  CAS  Google Scholar 

  118. Bosch JP, Luckenbill L. Capitation in nephrology: the time has come. Adv Renal Replacement Ther. 1997;4:325–31.

    CAS  Google Scholar 

  119. Jones ER. The new ESRD demonstration project on disease management. Nephrol News Issues. 2003;17:25–8.

    PubMed  Google Scholar 

  120. Crooks P. The First ESRD managed care demonstration project: a Kaiser Permanente view. Nephrol News Issues. 2003;17:29–35.

    PubMed  Google Scholar 

  121. Reynolds L. Update: HCFA ESRD managed care demonstration project. Nephrol News Issues. 2000;14:19–20.

    PubMed  CAS  Google Scholar 

  122. Hirth RA, Held PJ. Some of the small print on managed care proposals for end-stage renal disease. Adv Renal Replacement Ther. 1997;4:314–24.

    CAS  Google Scholar 

  123. Amerling R. Managed care is not the ‘cure-all’ for improving quality and controlling costs in ESRD. Nephrol News Issues. 1999;13;46–7.

    PubMed  CAS  Google Scholar 

  124. Amerling R. An alternative to global capitation for ESRD: global fee-for-service. Nephrol News Issues. 2000;14:15–16.

    PubMed  CAS  Google Scholar 

  125. Nissenson AR, Collins AJ, Dickmeyer J. Evaluation of disease-states management of dialysis patients. Am J Kidney Dis. 2001;37:938–44.

    Article  PubMed  CAS  Google Scholar 

  126. Nissenson AR. Outcomes associated with a disease management program for end-stage renal disease. Dis Manage Health Outcomes. 2002;10:93–100.

    Article  Google Scholar 

Download references

Authors
  1. P. G. Blake
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. M. Just
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Nephrology, Department of Medicine III, University of Vienna, Währinger Gurtel 18-20, A-1090, Vienna, Austria

    Walter H. Hörl

  2. Division of Nephrology, Centre for Internal Medicine and Dermatology, Medizinische Hochschule, Hannover, Germany

    Karl M. Koch

  3. Optimal Dialysis Research Unit, London Health Sciences Centre and The University of Western Ontario, London, Ontario, Canada

    Robert M. Lindsay

  4. Department of Nephrology, St. Bortolo Hospital, Viale Rodolfi, I-36100, Vicenza, Italy

    Claudio Ronco

  5. RenalTech International, LLC, 320 East 65th St, #116, New York, NY, 10021, USA

    James F. Winchester

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Blake, P.G., Just, P.M. (2004). Economics of dialysis. In: Hörl, W.H., Koch, K.M., Lindsay, R.M., Ronco, C., Winchester, J.F. (eds) Replacement of Renal Function by Dialysis. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-2275-3_62

Download citation

  • DOI: https://doi.org/10.1007/978-1-4020-2275-3_62

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-015-7012-1

  • Online ISBN: 978-1-4020-2275-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation